Charles B. O'Keeffe - Dec 9, 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director
Signature
/s/ Charles B. O'Keeffe
Stock symbol
CPRX
Transactions as of
Dec 9, 2024
Transactions value $
$160,400
Form type
4
Date filed
12/11/2024, 05:00 PM
Previous filing
Nov 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +1.41K +0.21% 687K Dec 9, 2024 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $160K +40K +5.82% $4.01 727K Dec 10, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -1.41K -0.55% $0.00 254K Dec 9, 2024 Common Stock 1.41K Direct F1, F2, F3
transaction CPRX Options to purchase common stock Options Exercise $0 -40K -15.77% $0.00 214K Dec 10, 2024 Common Stock 40K $4.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
F3 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.
F4 Options vested in three annual tranches beginning on January 2, 2019.